Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells 2,000 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 2,000 shares of the stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $25.33, for a total value of $50,660.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Benjamin Hohl also recently made the following trade(s):

• On Friday, September 27th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $24.27, for a total transaction of $103,147.50.
• On Tuesday, August 27th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.54, for a total transaction of $95,795.00.
• On Wednesday, July 31st, Benjamin Hohl sold 991 shares of Enliven Therapeutics stock. The stock was sold at an average price of $27.53, for a total transaction of $27,282.23.
• On Monday, July 29th, Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $26.68, for a total value of $140,070.00.
• On Friday, July 12th, Benjamin Hohl sold 3,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $25.07, for a total value of $75,210.00.

Enliven Therapeutics Price Performance

Shares of ELVN traded up $0.46 during mid-day trading on Tuesday, reaching $26.00. The stock had a trading volume of 849,423 shares, compared to its average volume of 257,450. The firm has a market cap of $1.22 billion, a price-to-earnings ratio of -14.14 and a beta of 1.09. The business’s fifty day moving average is $23.14 and its 200 day moving average is $21.71. Enliven Therapeutics, Inc. has a 52-week low of $9.80 and a 52-week high of $27.67.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.17. As a group, sell-side analysts anticipate that Enliven Therapeutics, Inc. will post -1.98 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ELVN. Janus Henderson Group PLC lifted its position in Enliven Therapeutics by 74.8% during the 1st quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock worth $12,604,000 after acquiring an additional 305,397 shares during the period. First Turn Management LLC acquired a new position in shares of Enliven Therapeutics in the second quarter worth $9,657,000. Marshall Wace LLP purchased a new stake in Enliven Therapeutics during the 2nd quarter worth about $4,489,000. Baker BROS. Advisors LP acquired a new position in shares of Enliven Therapeutics in the first quarter valued at approximately $2,020,000. Finally, Bank of New York Mellon Corp lifted its stake in shares of Enliven Therapeutics by 49.2% during the second quarter. Bank of New York Mellon Corp now owns 114,109 shares of the company’s stock valued at $2,667,000 after buying an additional 37,632 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Wall Street Analysts Forecast Growth

ELVN has been the topic of a number of research analyst reports. Baird R W raised shares of Enliven Therapeutics to a “strong-buy” rating in a research note on Tuesday, June 11th. Robert W. Baird began coverage on shares of Enliven Therapeutics in a research report on Tuesday, June 11th. They set an “outperform” rating and a $32.00 price target for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $37.00 price objective on shares of Enliven Therapeutics in a report on Tuesday.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.